Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 13/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.33 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612458 | 0.90 | PLA2G2A (0.44) | PLA2G2APLA2G1BADRA1DPLA2G10PARP1 | |
| SCHEMBL27507603 | 0.89 | FABP4 (0.40) | PLA2G2APLA2G1BPLA2G10FABP4PLA2G5 | |
| SCHEMBL27506049 | 0.88 | PLA2G2A (0.38) | PLA2G2APLA2G1BPLA2G10FABP4PLA2G5 | |
| SCHEMBL27506450 | 0.87 | CYP19A1 (0.40) | PLA2G2APLA2G10FABP4 | |
| SCHEMBL7050801 | 0.87 | PLA2G2A (0.43) | PLA2G2APARP1 | |
| SCHEMBL27526152 | 0.85 | PLA2G2A (0.41) | PLA2G2APLA2G1BADRA1DPLA2G10PARP1 | |
| SCHEMBL27505593 | 0.85 | PLA2G2A (0.46) | PLA2G2APLA2G1BPLA2G10FABP4PLA2G5 | |
| SCHEMBL27531157 | 0.85 | PLA2G2A (0.42) | PLA2G2APLA2G1BADRA1DPLA2G10FABP4 | |
| SCHEMBL28740873 | 0.85 | PLA2G2A (0.42) | PLA2G2APLA2G1BADRA1DPLA2G10PLA2G5 | |
| SCHEMBL27531171 | 0.85 | HTT (0.42) | PLA2G2APLA2G1BPLA2G10PARP1PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067579-A1 | ADIPOSITY-MODULATING MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-16 | — | — | WO | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | disclosed |